Allergic bronchopulmonary aspergillosis (ABPA) is a localized inflammatory airway disease seen in patients sensitized to antigens. The disease presents with productive cough, wheezing, episodic fever, as well as central bronchiectasis (CB) and mucus plugs on computed tomography (CT) scans. If treated accordingly, symptoms and pulmonary damage caused by ABPA can be reverted. Currently, the diagnostic criteria for ABPA require the diagnosis of predisposing pulmonary diseases such as asthma and cystic fibrosis (CF) in order to establish the diagnosis. There has been an increasing number of cases reporting ABPA without evidence of past asthmatic history or symptoms. This reflects the need for more sensitive diagnostic tests in order to prevent progression to irreversible lung injury. Here we report a 22-year-old Puerto Rican male who went undiagnosed for ABPA for 12 months due to the absence of asthma or CF history.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262577 | PMC |
| http://dx.doi.org/10.7759/cureus.15498 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Bronchiectasis in patients with severe asthma : a narrative literature review].
Rev Med Liege
January 2025
Service de Pneumologie, CHU Liège, Belgique.
Asthma is a common respiratory disease, accounting for 3 to 10 % of severe cases. Among these, bronchiectasis is more frequent (prevalence between 15.5 % and 67.
View Article and Find Full Text PDFPrevalence and features of allergic bronchopulmonary aspergillosis, United States, 2016-2022.
PLoS One
January 2025
Asthma and Air Quality Branch, Division of Environmental Health Science and Practice, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
The epidemiology of allergic bronchopulmonary aspergillosis (ABPA) in the United States is not well-described. To estimate national ABPA prevalence among patients with asthma or cystic fibrosis, characterize ABPA testing practices, and describe ABPA clinical features, treatment, and 6-month outcomes. We used the 2016-2022 Merative™ MarketScan® Commercial/Medicare and Multi-State Medicaid Databases to identify cohorts of patients with 1) asthma, 2) cystic fibrosis (CF), and 3) ABPA.
View Article and Find Full Text PDFCorrelation of Sensitization with Mucus Plugging in COPD.
Int J Chron Obstruct Pulmon Dis
January 2025
Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, People's Republic of China.
Background: Both sensitization and mucus plugs are associated with poor clinical outcomes in COPD. However, little is known about the association between hypersensitivity and mucus plugging in patients with COPD.
Methods: We retrospectively enrolled COPD patients who had visited Peking University Third Hospital and received measurement of the specific IgE ( sIgE) from Oct 1, 2018 to Sep 30, 2023.
An immunological perspective in the treatment strategy of allergic bronchopulmonary aspergillosis.
QJM
January 2025
Flat 6 Souchay Court, 1 Clothorn Road, Manchester, M20 6BR.
Pulmonary overlap syndrome in a patient with bronchial asthma.
BMJ Case Rep
January 2025
Pulmonary, Critical Care and Sleep Medicine, ESICPGIMSR, New Delhi, Delhi, India.
Allergic bronchopulmonary aspergillosis (ABPA) is a disease of immunocompetent patients, and invasive pulmonary aspergillosis is seen in immunocompromised patients. Hence, pulmonary overlap syndrome presenting with ABPA and invasive aspergillosis is extremely rare. We report a case of well-controlled bronchial asthma who presented with acute exacerbation and hypoxaemic respiratory failure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!